KCNT1 (KNa1.1/Slack) channel

Class

potent, selective, orally available small-molecule KCNT1 ion channel inhibitor

Pathway

inhibits the overactive KCNT1 potassium channel caused by gain-of-function KCNT1 mutations, reducing the resulting neuronal hyperexcitability and seizures

KCNT1, also called Slack or KNa1.1, is a potassium channel that opens in response to rising intracellular sodium concentration and helps set the pace and pattern of neuronal firing, particularly by shaping the after-hyperpolarization that follows an action potential. Certain inherited or de novo mutations make this channel gain of function, meaning it conducts excessive potassium current. Counterintuitively, this does not simply quiet neurons; it appears to disproportionately dampen inhibitory (GABAergic) interneurons, tipping brain circuits toward excessive, synchronized firing. Clinically, KCNT1 gain-of-function mutations are linked to severe early-onset epilepsies, including epilepsy of infancy with migrating focal seizures, and to certain forms of frontal lobe epilepsy, conditions typically marked by frequent, treatment-resistant seizures and developmental impact. A selective small-molecule inhibitor of KCNT1 aims to normalize the excessive channel activity at its source, rather than broadly suppressing neuronal excitability the way many older anti-seizure medicines do. Because the defect is a specific gain of function in a single channel, direct pharmacological inhibition offers a more mechanistically targeted approach than general sodium- or calcium-channel blockers, with the goal of reducing seizure frequency while preserving normal neuronal function elsewhere in the brain.